title: [Obesity and type 2 diabetes].
abstract: Obesity and Type 2 Diabetes are nowadays summarized as "diabesity". That is due to the fact that obesity is frequently preceding and the most important risk factor in the increase of Type 2 Diabetes. The body mass index (BMI) is a crude measure of body fatness. Even normal weight persons can have lack in muscles (sarcopenia), which leads to the recommendation to measure waist und body fatness (e.g. BIA). Lifestyle management including nutrition and physical activity are important for diabetes prevention. In the therapy of Type 2 Diabetes body weight is increasingly used as secondary target. Also the choice of the anti-diabetic medication and concomitant medications is increasingly influenced by body weight. The significance of anti-obesity medications in the therapy of type 2 diabetes will have to be clarified by future studies. Bariatric surgery is at present indicated with a BMI above BMI > 35 kg/m(2) and can lead at least to partial diabetes remission but has to be part of a lifelong care concept.
authors.affiliation: Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich. hermann.toplak@medunigraz.at.
authors.forename: Hermann
authors.initials: H
authors.lastname: Toplak
authors.affiliation: Abteilung für Innere Medizin, Krankenhaus der Barmherzigen Brüder, Salzburg, Österreich.
authors.forename: Friedrich
authors.initials: F
authors.lastname: Hoppichler
authors.affiliation: 1. Medizinische Abteilung, Hanuschkrankenhaus, Wien, Österreich.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Wascher
authors.affiliation: Klinische Abteilung für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
authors.forename: Karin
authors.initials: K
authors.lastname: Schindler
authors.affiliation: Abteilung für Innere Medizin, Krankenanstalt Rudolfstiftung der Stadt Wien, Wien, Österreich.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Ludvik
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage; D001317:Austria; D050110:Bariatric Surgery / Q000592:standards; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D004035:Diet Therapy / Q000592:standards*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005081:Exercise Therapy / Q000592:standards*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D009765:Obesity / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D017410:Practice Guidelines as Topic; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
chemical_list: D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents
keywords: Obesity; Typ 2 diabetes